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Abstract
Background: In man, elevated levels of plasma plipoprotein (a)(Lp(a))  is a cardiovascular risk
factor, and oxidized phospholipids are believed to play a role as modulators of inflammatory
processes such as atherosclerosis. Polyamines are potent antioxidants and anti-inflammatory
agents. It was therefore of interest to examine polyamines and their metabolism in LPA transgenic
mice.
Concentration of the polyamines putrescine, spermidine and spermine as well as the activity of
peroxisomal polyamine oxidase and two other peroxisomal enzymes, acyl-CoA oxidase and
catalase were measured. The mice were fed either a standard diet or a diet high in fat and
cholesterol (HFHC). Some of the mice in each feeding group were in addition given aminoguanidine
(AG), a specific inhibitor of diamine oxidase, which catalyses degradation of putrescine, and also
inhibits non-enzymatic glycosylation of protein which is implicated in the aetiology of
atherosclerosis in diabetic patients. Non-transgenic mice were used as controls.
Results:  Intestinal peroxisomal polyamine oxidase activity was significantly higher in LPA
transgenic mice than in the non-transgenic mice, while intestinal peroxisomal catalase activity was
significantly lower. Hepatic β-oxidation increased in Lp(a) transgenic mice fed the HFHC diet, but
not in those on standard diet.
Hepatic spermidine concentration was increased in all mice fed the HFHC diet compared to those
fed a standard diet, while spermine concentration was decreased. With exception of the group fed
only standard diet, transgenic mice showed a lower degree of hepatic steatosis than non-transgenic
mice. AG had no significant effect on hepatic steatosis.
Conclusion: The present results indicate a connection between peroxisomal enzyme activity and
the presence of the human LPA gene in the murine genome. The effect may be a result of changes
in oxidative processes in lipid metabolism rather than resulting from a direct effect of the LPA
construct on the peroximal gene expression.
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Background
Elevated levels of plasma lipoprotein (a) Lp(a) are a sig-
nificant cardiovascular risk factor in man [1]. We have ear-
lier reported development of arteriosclerosis in aorta of
mice transgenic for cDNA representing the human gene
for Lp(a), hLPA, on a standard diet [2,3], while the non-
transgenic mice only sporadically developed arteriosclero-
sis. In the LPA cDNA-transgenic animals, apolipopro-
tein(a), (apo(a)), occurs free in plasma, and we found a
significant correlation between the plasma apo(a) con-
centration and the size of aortic lesions.
The present investigation, based on tissue samples from
the animals in the above-mentioned study, was under-
taken to uncover if polyamines could influence on the
atherosclerotic development. There were no leftovers of
blood and the aortic wall for polyamine measurements.
The liver and kidney were therefore chosen.
The rationale for examining the polyamines, spermidine
and spermine, is that their positive charges strongly inter-
act with phospholipids and inhibit lipid peroxidation [4],
and to a certain extent protect liposome from oxidation
[5]. In addition, spermine exhibits an anti-inflammatory
effect [5] and exerts an antagonistic action on platelet
aggregation [6]. Since cell proliferation in the vascular
walls is important in the development of atherosclerotic
lesions, knowledge of levels and metabolism of
polyamines are per se of interest because of their well-
known importance for cell growth and differentiation. In
addition it was of interest to measure the activity of the
peroxisomal polyamine oxidase, an enzyme important in
converting polyamines [7]. Examination of the activity of
peroxisomal enzymes was of interest also because the per-
oxisomal proliferators activated receptors (PPARs) are
known to be involved in the development of arterioscle-
rosis (for review, see [8]. We have earlier shown that feed-
ing rats a diet enriched in polyamines resulted in a
decrease in hepatic polyamine oxidase and catalase activ-
ity, which could be restored by simultaneously supple-
menting the diet with clofibrate, a peroxisomal
proliferator and a hypolipidemic drug [9].
The fact that the hypolipidemic drug, clofibrate, changed
the activity of polyamine oxidase indicates that the fat
content of tissues may influence polyamine metabolism.
It was therefore of special interest to examine if fat loading
had any effect on liver polyamine content, and on
polyamine oxidase activity.
In the present study we found that polyamine oxidase
activity was higher in transgenic mice than in non-trans-
genic animals. In order to examine whether this reflects a
general increase in peroxisomal enzymes, we measured
the activity of two other peroxisomal enzymes, catalase
and β-oxidase. Catalase decomposes H2O2, a product of
oxidase activity, and thereby protects the cell against the
toxic effect of H2O2, while peroxisomal β-oxidation plays
the important physiological role of oxidation very long
fatty acids and the side chain of cholesterol.
Some groups of mice were treated with AG because AG
inhibits the formation of non-enzymatic glycosylation of
proteins [10], which are implicated in the aetiology of dia-
betic complications, including arteriosclerosis [10,11],
and because AG is a well-known specific inhibitor of
diamine oxidase, which catalyses degradation of
putrescine, the precursor of the polyamines; spermidine
and spermine.
We here report that the introduction of the human LPA
gene into FVB mouse resulted in no significant changes in
the polyamine concentration in liver and kidneys, but it
changed the activity of three peroxisomale enzymes
namely: intestinal polyaminoxidase and catalase and
hepatic acyl-CoA oxidase (responsible for β-oxidation).
There seemed to be less hepatic steatosis in the transgenic
mice compared to the control FVB mice.
In mice fed a HFHC diet compared to those fed a standard
low fat diet, the hepatic spermidine and spermine concen-
trations were different, resulting in a lower ratio between
spermidine and spermine concentrations in the HFHC fed
mice.
Results
The results did not suggest a sex difference with respect to
any of the measured parameters.
Body weight
Body-weight decreased by 2–5% during the experimental
period. Animals treated with aminoguanidine showed the
highest weight-loss. The reduction in the body weight
may be related to the relatively high age of the mice. Mice
on the high fat diet, showed an intermittent increase in
body weight of 2–9%, with a peak about 3 weeks after
start. However, mean body weight at the end of the treat-
ment period, was not significantly different from those of
the groups fed a standard diet (data not shown).
Polyamine oxidase activity
The small intestinal polyaminoxidase activity was signifi-
cantly (p < 0.05) higher in the transgenic mouse groups
than in the non-transgenic. The polyamine oxidase activ-
ity in the small intestine was about twice as high as in the
liver. Data showing the effects of the treatments on intes-
tinal polyamine oxidase activity are presented in Fig 1.
Hepatic polyamine oxidase activity was 0.41 ± 0.06 nmol/
min·mg and was not affected by the diet fat content, AG
treatment, or transgenity.Lipids in Health and Disease 2005, 4:23 http://www.lipidworld.com/content/4/1/23
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Catalase activity
Figure 2 shows the catalase activity measured in homoge-
nates from the small intestine. In all treatment groups the
catalase activity in the transgenic animals was significant
lower than in the non-transgenic mice. In transgenic mice,
given aminoguanidine in the drinking water, the catalase
activity was significantly higher in those on the HFHC diet
than in those on the standard diet (Fig. 2). AG treatment
of transgenic mice on the standard diet reduced the intes-
tinal catalase activity significantly.
There were only minor and insignificant differences in
hepatic catalase activity between transgenic and non-
transgenic mice and between the two diets. The activity
was roughly the same as in the small intestine of non-
transgenic mice.
AG in the drinking water to mice on the HFHC diet
resulted in an increased hepatic catalase activity from
about 1.5 to 3.0 µmol H2O2/s·mg protein.
Peroxisomal β-oxidation (hepatic acyl-CoA oxidase 
activity)
Peroxisomal β-oxidation in livers of transgenic mice fed
the HFHC diet and aminoguanidine in the drinking water
was significantly (p < 0.05) higher than in the non-trans-
genic mice on the same treatment (Fig. 3). In correspond-
ing experiment with mice on the same diet, but without
Intestinal polyamine oxidase activity in LPA transgenic and non-transgenic mice Figure 1
Intestinal polyamine oxidase activity in LPA transgenic and non-transgenic mice. The mice were fed two different diets, one 
high in fat and cholesterol (HFHC diet), the other a standard diet low in fat. Some of the animals from each group (see Table 1) 
were treated with 0.5% AG (aminiguanidine) in the drinking water. After 100 days of treatment the activity of the enzyme was 
assayed. The number of mice in each group is given with numbers within each column. Experimental details are given in Mate-
rials and Methods. The histograms represent means with SD indicated. Population means that were significantly different from 
the non-transgenic mice are denoted with asterisk, * (p < 0.05).
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aminoguanidine (Fig. 3), the difference observed did not
reach statistical significance.
Intestinal diamine oxidase activity
The diamine oxidase activity in the proximal part of the
small intestine was powerfully inhibited in animals given
AG, irrespective of their genetic status. The mean ± SD val-
ues of diamine oxidase activity expressed as amount
putrescine turnover pr. min and g tissue was 220 ± 160
and 17 200 ± 6200 pmol for the aminoguanidine treated
and the non-treated animals, respectively. This is in agree-
ment with the established inhibitory effect of aminogua-
nidine on diamine oxidase activity [12].
Tissue polyamines
The hepatic concentrations of putrescine wearied around
the level of detection of the assay. Evaluation of these data
could therefore not be carried out.
With exception of mice on standard diet and aminoguani-
dine treatment, transgenic and non-transgenic mice
exhibited no significant differences in hepatic spermidine
and spermine concentrations (Figs. 4 and 5)
The hepatic concentration of spermidine in mice fed the
atherogenic diet, HFHC; was significantly (p < 0.05) lower
than in mice given standard diet (Fig. 4). On the other
hand, a slight, but significant increase (p < 0.05) in sper-
mine concentration was observed in mice fed the HFHC
diet without AG in the drinking water, compared to those
fed the standard diet (Fig. 5). The spermidine/spermine
ratio was 0.76 for mice on the HFHC diet, and 1.32 for
those on standard diet.
In kidney there were no differences between transgenic
and non-transgenic mice. Thus for the non-transgenic
mice the putrescine, spermidine and spermine concentra-
tions were (73 ± 36) nmol/g, (363 ± 83) nmol/g and (606
± 101) nmol/g, respectively, and the corresponding values
for the transgenic animals were 66 ± 22, 398 ± 170 and
642 ± 154 nmol/g. Furthermore, there was no difference
between mice on the two diets, or between AG treated and
untreated mice.
Hepatic steatosis
In the fatty infiltrations, there was no sign of inflamma-
tory cells. Hepatic steatosis was graded from 1 to 3.
Intestinal catalase activity in LPA transgenic and non-transgenic mice Figure 2
Intestinal catalase activity in LPA transgenic and non-transgenic mice. The histograms represent means with SD indicated. Pop-
ulation means that were significantly different from the non-transgenic mice (p < 0.05) are denoted with *. Population means 
denoted with • indicate difference from the corresponding mice fed the HFHC diet and  indicate significant differences from 
the corresponding aminoguanidine (AG) treated mice. Experimental details are given in the legend to Fig. 1 and in Materials and 
Methods section.
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Typical sections of liver with steatosis of grade 1, 2 and 3,
together with sections of a normal liver are shown in Fig.
6. Steatosis occurred in the liver of all, but four mice. The
grade of steatosis was lower in the transgenic mice than in
non-transgenic mice, but the difference was statistical sig-
nificant (p < 0.05) only for those on a standard diet with
AG in the drinking water and for those fed only a high fat
diet (Fig. 7).
Discussion
Enzyme activities
Introduction of cDNA representing the LPA gene together
with the transferrin promotor, into the mouse genome
resulted in changes in activity of the peroxisomale
enzymes polyamine oxidase and catalase in the small
intestine, but not in the liver (Figs. 2, 3, 4). This is in con-
trast to the fact that the LPA gene is expressed in liver, but
not in the intestines [13], indicating that the effect on the
intestinal enzymes must be secondary. Since the genes
coding for polyamine oxidase (Locus ID no Mm 212503)
and for acyl-CoA oxidase (Locus ID no. Mm 11430) are
located on different mouse chromosomes, 7 and 11,
respectively, it is unlikely that the observed changes in
these enzyme activities were caused by the introduction of
the LPA gene with a transferrin promotor, in or near the
regulator region of the gene for these enzymes.
The increased intestinal polyamine oxidase activity in LPA
transgenic mice compared to non-transgenic mice (Fig. 1),
indicates an altered peroxisomal polyamine metabolism.
When the activity of the H2O2 producing polyamine oxi-
dase enzyme is increased in the transgenic mice, an
increase in the catalase activity should be anticipated.
However, the opposite was the case.(Fig. 2) Increased
polyamine oxidase activity can therefore not be explained
by a general increase in activity of peroxisomal enzymes.
The increase in H2O2  production from enhanced
polyamine oxidase activity is probably marginal, com-
pared with H2O2 production from other sources. The
observed changes in hepatic peroxisomal β-oxidation
(Fig. 3) cannot explain the decrease in the catalase activity
because peroxisomal β-oxidation did not change in the
control mice and even increased in the LPA-transgenic
mice on HFHC diet. The increased peroxisomal β-oxida-
Hepatic peroxisomal β-oxidation activity in LPA transgenic mice and non-transgenic mice Figure 3
Hepatic peroxisomal β-oxidation activity in LPA transgenic mice and non-transgenic mice. Experimental details are given in the 
legend to Fig. 1 and in Materials and Methods section. The histograms represent means with SD indicated. Population means 
that were significantly different (p < 0.05) from non-transgenic mice are denoted with *. Population means denoted with ♦ 
indicate significant differentce from the corresponding mice fed a HFHC diet.
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tion in LPA transgenic mice on the HFHC diet is in agree-
ment with reports showing that diets high in fat, particular
those containing hydrogenated fat, cause increased of per-
oxisomal β-oxidation [14,15]. In non-transgenic mice the
same diet caused no significant increase of peroxisomal β-
oxidation. It follows that mice, transgenic with respect to
LPA may be more prone than non-transgenic mice to
increase of peroxisomal β-oxidation probably because of
the low fat content (Fig. 2).
The observed increase in polyamine oxidase and β-oxi-
dase activity together with a decrease in catalase activity
indicate that also other oxidative processes are changed as
a result of the introduction of the LPA gene. This seems
interesting in the view of the possible role of oxidized
phospholipids as modulators of inflammatory processes.
Thus, modified phospholipids accumulate at sites of
inflammation such as atherosclerotic lesions [16]. Fur-
thermore, oxidized phospholipids are shown to induce
expression of atherosclerosis-related genes [17]. Addi-
tional evidence has been provided by the use of murine
natural monoclonal IgM antibody, EO6, which binds to
oxidation-specific epitopes on oxidized low-density lipo-
protein. A high correlation between plasma Lp(a) and
EO6 was then found [18].
The conclusion so far must be that changes in the three
peroxisomal enzyme activities in LPA-transgenic mice is
more likely to be caused by altered lipid metabolism in
these animals, rather than by a direct effect of the LPA con-
struction on the expression of the peroxisomal genes.
Polyamines
In the kidneys, neither the LPA gene nor the HFHC diet
and AG treatment seemed to influence the polyamine lev-
els significantly (data not shown).
Hepatic spermidine concentration in LPA transgenic and non-transgenic mice Figure 4
Hepatic spermidine concentration in LPA transgenic and non-transgenic mice. The columns represent means with SD indi-
cated. Population mean that is significantly different from that of non-transgenic mice is denoted with asterisk, *. ∆ Indicate sig-
nificant difference from the corresponding groups fed a standard diet. Experimental details are given in the legend to Fig 1 and 
in the Materials and Methods section.
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The hepatic spermidine and spermine concentration were
almost unaffected by aminoguanidine treatment (Fig. 4
and 5). The same was true for the kidneys. Although the
polyamine concentration in the standard diet was much
higher than in the HFHC diet, the HFHC diet resulted in
higher hepatic spermidine concentration. It seems not
likely that differences in the intestinal micro flora caused
the observed differences in hepatic polyamine content
between the two feeding groups.
Clofibrate treatment, that decreases plasma lipid levels
has earlier been found to increase the hepatic content of
spermidine and reduce that of spermine [9], which is con-
trary to the effect of the HFHC diet.
The HFHC fed group had higher levels of hepatic fat, as
judged by the amount of fat filled vacuoles (steatosis)
than those on the standard diet. However, we found no
significant correlation between hepatic steatosis and
hepatic levels of spermidine or spermine. In spite of that,
we suggest that hepatic lipid level may be of importance
for the hepatic polyamine level. The fact that spermine
binds to negatively charged lipids, e.g. phospholipids [19]
may in part explain the increased spermine concentration
in liver.
Spermidine in plasma can bind to HDL [20], which is
known to inhibit the formation of oxidized low-density
lipoprotein (LDL) [21]. Polyamines, especially spermine,
are also potent antioxidants and anti-inflammatory agents
[5]. The polyamine concentrations have further been
reported to inhibit platelet aggregation in hypercholester-
olemic rabbits [6]. Studies of the role of polyamines in
atherogenesis/thrombogenesis are therefore called for.
The spermidine/spermine ratio is known to be high in fast
growing tissue. Thus, in rat liver at birth the ratio is 4.5,
whereas this ratio at 9 months is 0.8 [22]. One can only
speculate if the cell turnover rate for liver cells in mice fed
the HFHC diet, that have a hepatic spermidine/spermine
Hepatic spermine concentration in LPA transgenic and non-transgenic mice Figure 5
Hepatic spermine concentration in LPA transgenic and non-transgenic mice. The columns represent means with SD indicated. 
Population mean that is significantly different (p < 0.05) from that of the non-transgenic mice is denoted with asterisk, *. ∆ Indi-
cate significant difference (p < 0.05) from the corresponding HFHC fed groups. Experimental details are given in the legend to 
Fig. 1 and in the Materials and Methods section.
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ratio on 0.76, is reduced compared to that of mice on a
standard diet where the corresponding ratio was 1.32.
Liver steatosis
For two of the feeding groups there was significantly lower
degree of hepatic steatosis in the transgenic mice than in
the non-transgenic animals (Fig 7) suggesting differences
in lipid metabolism. We have earlier reported a signifi-
cantly higher rate of aortic lesions in LPA transgenic mice
than in non-transgenic animals and a positive correlation
between apo(a) level and size of aortic lesions [2,3]. This,
together with the fact that inflammatory cells only could
be seen in the aortic fat infiltrations, not in that of the
liver, indicate that there are different mechanisms
involved in the deposition of lipids in aortic lesions and
in liver cells.
The AG treated mice on the HFHC diet had less steatosis
than the untreated animals but the differences were far
from significant. This indicates that glycosylation is not
participating in the formation of hepatic steatosis in mice.
Conclusion
An increase in polyamine oxidase activity in hLPA trans-
genic mice, and an increase in β-oxidation in transgenic
mice fed a HFHC diet, together with a decrease in catalase
activity may indicate that also other oxidative processes
are changed as a result of the introduction of the LPA
gene. Such changes would be of great interest because oxi-
dation products are known to be important in the devel-
opment of arteriosclerosis.
Changes in the polyamine pattern upon increased fat
intake are also noteworthy. However, in this study we
have not been able to show any connection between
polyamines/polyamine-metabolism and the arterioscle-
rotic lesion seen in the same mice [2,3]. Further studies
are warranted.
Materials and methods
Reagents
Horseradish peroxidase (EC 1. 11. 1. 7) (Type VI. RZ
between 250 and 330 U/mg), N1-acetyl-spermine, 4-ami-
noantipyrine, palmitoyl-CoA, NAD+, FAD, HEPES, hexan-
ediamine, putrescine 2HCl, spermidine 3HCl, spermine
4HCl, and mannitol were purchased from Sigma Chemi-
cal Co. (St. Louis, MO., USA). Perhydrol (H2O2) was
obtained from E. Merck (Darmstadt, Germany). All other
reagents were of analytical grade. [1,4-14C]-Putrescine
dihydrochloride (spes.act. 2.11 GBq/mmol) was obtained
from Amersham Pharmacia Biotech, Ltd. (Rainham,
Essex, UK).
Scoring of hepatic steatosis Figure 6
Scoring of hepatic steatosis. A) Normal liver with no lipid 
deposits, grade 0, B) Liver tissue with steatosis grade 1 (slight 
steatosis), C) grade 2, that between slight and serve stearo-
sis, D) Liver tissue with steatosis grade 3 (serve steatisis), 
almost all cells are affected and many with large fat vacuoles. 
Magnification 1000x.
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Animals and feeding
This stock of mice have also been used in a parallel inves-
tigation of effects of the LPA gene on the development of
aortic lesions [2,3]. Forty-one transgenic mice with cDNA
representing the human LPA gene linked to the mouse
transferrin promotor were studied. The mice were of a
hybrid genetic background of strain C57BL/6 crossed with
strain SJL [2,3]. The original transgenic breeder mice were
a generous gift from Dr. Richard M. Lawn, Falk Cardiovas-
cular Research Center, Stanford University, CA., USA.
Twenty-nine non-transgenic littermates from breeding
between transgenic and non-transgenic mice were used as
controls. DNA analyses of white blood cells were per-
formed to ascertain the LPA transgenic status of the mice.
The mice were of both sexes and between 49 and 67 weeks
of age when the study started (see Table 1).
Half of the animals were fed a standard mouse diet (RMI
(E) SQS, Special Diets Services, Witham, Essex, England)
containing 2.6% fat (crude oil), where saturated fat
accounted for 20%. The other half of the animals, were
fed an atherogenic semi-purified diet high in fat and cho-
lesterol (HFHC diet), containing 1.25% cholesterol,
18.4% regular butter and 0.5% sodium cholate (ICN
Pharmaceuticals, Inc. 1731 Asse-Relegem, Belgium). Sev-
eral of the animals on each diet were given 0.1% (w/v)
aminoguanidine in the drinking water (Table 1). All the
treatments lasted for 100 days.
The amounts of polyamines in the standard diet were: 110
nmol/g putrescine, 240 nmol/g spermidine and 45 nmol/
g spermine. The corresponding figures for putrescine and
spermidine in the HFHC diet were 1.0 and 3.5 nmol/g,
respectively. Spermine could not be detected.
Females and males were housed separately, with 1–5 mice
per cage. They had a 12 hrs. light/dark cycle, a constant
temperature of 21°C and a relative humidity of 65%. Sen-
tinel mice were used to run a FELASA-style health-moni-
toring scheme. The mice were clinically healthy
throughout the experimental period. The mice were raised
in The Laboratory Animal Unit at Norwegian School of
Veterinary Science (accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care
Hepatic steatosis (grade 0 to 3) in LPA transgenic and non-transgenic mice Figure 7
Hepatic steatosis (grade 0 to 3) in LPA transgenic and non-transgenic mice. The columns represent means with SD indicated. 
Population means that are significantly (p < 0.05) different from the non-transgenic mice are denoted with asterisks, *. Experi-
mental details are given in the legend to Fig. 1 and in the Materials and Methods section.
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and Use International, Brussels, Belgium), and they were
kept according to the regulations of the Norwegian Gene
Technology Act of 1994. The study was approved by the
Norwegian Animal Research Authority.
Blood sampling and preparation of tissue samples for 
enzyme measurements
The mice were anaesthetized by a subcutaneous injection
of 0.05 ml/10 g body-weight of a 1:1 mixture of Fenatyl/
Midazolum (Hypnorm "Janssen" diluted 10x with water
and Dormicum "Roche" 5 mg/ml) prior to blood
sampling, which was done by an incision in vena saphena.
The mice were afterwards killed by neck dislocation, and
tissues for analysis were removed as quickly as possible.
After removal, the liver was weighed, and transferred into
ice-cold mannitol-medium (300 mmol/L mannitol, 25
mmol/L HEPES, 1 mmol/L EGTA, pH 7.2). A 10% (w/v)
homogenate was prepared by 2 strokes in a Potter-Elve-
hjem homogenizer equipped with a Teflon® piston. The
homogenate was centrifuged for 1 min at 1075 × gav. The
resulting supernatants were transferred into several small
vials, and stored at -20°C until analyzed.
A 20 cm long proximal segment of the small intestine,
starting about 0.5 cm from the pyloric sphincter, was pre-
pared. It was cut open longitudinally, rinsed with ice-cold
0.9% (w/v) NaCl, blotted against filter paper, and homog-
enized for 15 s in ice-cold mannitol medium with an
Ultra-Turrax® at 25,000 rpm. The resulting homogenate
was subsequently centrifuged at 1075 × gav for 15 min and
the supernatant was stored at -20°C until it was analyzed.
Prior to assays, one part of the homogenate was mixed
with one part of ice-cold mannitol medium, and then Tri-
ton X-100 was added to a resulting concentration of
0.05% (v/v).
Enzyme assays
Catalase (EC 1.11.1.6) activity was assayed by monitoring
the decomposition of H2O2 at 240 nm and 25°C essen-
tially as described by Bergmeyer et  al [23]. Catalase is
labile in dilute solution. Therefore, homogenates were
diluted 10 times with 20 mmol/L potassium phosphate
buffer, pH 7.4 immediately prior to analysis.
Peroxisomal β-oxidation was assayed as palmitoyl-CoA-
dependent NAD+-reduction, according to Hovik and
Osmundsen [24]. Polyamine oxidase (polyamine: oxygen
oxidoreductase, EC 1.5.3.3) was assayed spectrophoto-
metrically as described by Hayashi et al. [25]. Diamine
oxidase, EC 1.4.3.6 was determined radiometrically, as
described by Okuyama and Kobayashi [26].
Catalase activity, peroxisomal β-oxidation and polyamine
oxidase activity were measured in 6 randomly selected
mice from each of 7 groups of animals, whereas all 5 mice
in the transgenic group on HFHC diet and AG were exam-
ined. As seen in Fig. 3 the numbers of mice in some other
groups were also less than 6, due to accidental loss of
some samples.
Polyamine assays
Tissue specimens were weighed and thereafter homoge-
nized in 4 volumes of 5% trichloroacetic acid. Hexane
diamine was added as an internal standard. The homoge-
nates were kept on ice for 1 hr, followed by centrifugation
at 2°C for 10 min at 5000 gav. The supernatant was stored
at -20°C until analyzed. The polyamines were dansylated
[27,28] and separated by HPLC [29] on a Radial PAK-A
column (Waters, Milford, Ma., USA).
Assay of proteins
Protein assay were carried out using the biuret method
[30] with Boehringer Precimat (Boehringer Mannheim,
Mannheim, Germany) as protein standard.
Liver steatosis
Liver tissue for morphometric studies were removed and
immediately placed in a buffered formaldehyde solution.
The examination was made routinely on sections of liver,
in paraffin blocks, stained with Oil red O and counter-
stained with hematoxylin. Hepatic steatosis was identified
by light microscopy as empty vacuoles in the cytoplasm of
Table 1: Diet, treatments, age and sex distribution of LPA transgenic and non-transgenic mice
Non-transgenic mice Transgenic mice
Diet and treatment No. Sex Age (days), 
mean ± SD
No. Sex Age (days), 
mean ± SD
Standard 12 F 6, M 6 481 ± 46 11 F 4, M 7 469 ± 36
Standard + aminoguanidine 9 F 5, M 4 501 ± 55 7 F 3, M 4 498 ± 53
HFHC 11 F 8, M 3 467 ± 16 17 F 8, M 9 486 ± 42
HFHC + aminoguanidine 7 F 5, M 2 498 ± 51 5 F 2, M 3 476 ± 20
F = females
M = malesLipids in Health and Disease 2005, 4:23 http://www.lipidworld.com/content/4/1/23
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liver cells (Fig. 7). For definitive identification of lipid,
frozen sections from separate specimens were stained
with Oil Red O. The same pathologist examined the sec-
tions blindly, and all measurements were performed four
times. The evaluation of visible fat in the liver cells was
assessed using a semi quantitative scale from 0 to 3. Zero
indicates that no vacuolated liver cells could be detected.
In the slightest degree of steatosis (grade 1) tiny vacuoles
are found in small parts of the lobule, whereas in the
severe case (grade 3) almost every liver cell is affected and
most cells have large vacuoles. "Moderate" (grade 2)
denotes fatty changes between that of slight and severe
steatosis (Fig. 7).
Statistical analysis
To calculate the significance of differences between non-
transgenic and transgenic mice on the same treatment we
used an unpaired, two tailed t-test, employing the Graph-
Pad Prism v.2.0 program (GraphPad software Inc., San
Diego, USA).
The values given in the text and legends to Figures are
means, with SD as indicated.
List of abbreviations
AGE, advanced glycosoationtion end products; AG,
aminoguanidine; HFHC, diet high in fat and cholesterol;
LPA, gene encoding apo(a).
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